LOGIN  |  REGISTER
Chimerix
Cue Biopharma

Bausch + Lomb Will Release First-Quarter 2023 Financial Results on May 3

April 17, 2023 | Last Trade: US$13.88 0.32 -2.25

VAUGHAN, Ontario / Apr 17, 2023 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter 2023 financial results on Wednesday, May 3, 2023. Bausch + Lomb will host a conference call and live web cast at 8:00 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call.

Conference Call Details

Date:

     

Wednesday, May 3, 2023

Time:

     

8:00 a.m. ET

Webcast:

     

https://www.webcaster4.com/Webcast/Page/2883/47444

Participant Event Dial-in:

     

+1 (888) 506-0062 (North America)

+1 (973) 528-0011 (International)

Participant Access Code:

     

937525

Replay Dial-in:

     

+1 (877) 481-4010 (North America)

+1 (919) 882-2331 (International)

Replay Passcode:

     

47444 (replay available until May 17, 2023)

About Bausch + Lomb

Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on Twitter, LinkedIn, Facebook and Instagram.

© 2023 Bausch & Lomb Incorporated or its affiliates.

Recursion

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page